Oxford BioTherapeutics
  • ABOUT
    • OUR TEAM
    • BOARD OF DIRECTORS
    • INVESTORS
    • OFFICES & LABS
  • PIPELINES
    • INTERNAL PROGRAMS
    • PARTNERED PROGRAMS
  • PARTNERSHIPS
  • OUR SCIENCE
    • IO DISCOVERY PLATFORM >
      • IMMUNE CHECKPOINT TARGETS
      • IO ANTIBODY ENGINEERING
    • OGAP DISCOVERY PLATFORM
  • CAREERS
  • NEWS
    • PRESS RELEASES
  • CONTACT

EVENTS

Upcoming Events

​2022

Date
Event
Details
20 Sept 2021
 Boehringer Ingelheim and Oxford BioTherapeutics Partnership Advances Second Oncology Drug Candidate into the Clinic
View here
19 Jan 2021
Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics' WuXiBody® Platform
View here
06 Jan 2021
Kite and Oxford BioTherapeutics Establish Cell therapy Research Collaboration in Blood Cancers and Solid Tumours
View here
MEDIA
Immunotherapies Expose and Exploit Cancer’s Varied Weaknesses
March 18 2021: 
“If we could understand why some people reengage their immune system after receiving chemotherapy, while others don’t, we could think about how to combine various therapeutic modalities and in what sequence”, says Christian Rohlff, PhD, CEO of Oxford BioTherapeutics. Read more here about how OBT uses proprietary immuno-oncology technology and antibody-drug conjugates to develop novel therapeutics that can reengage the immune system to destroy cancer cells.

Privacy Policy

Legal Notice

Site Map

© 2017 Oxford BioTherapeutics All Rights Reserved
  • ABOUT
    • OUR TEAM
    • BOARD OF DIRECTORS
    • INVESTORS
    • OFFICES & LABS
  • PIPELINES
    • INTERNAL PROGRAMS
    • PARTNERED PROGRAMS
  • PARTNERSHIPS
  • OUR SCIENCE
    • IO DISCOVERY PLATFORM >
      • IMMUNE CHECKPOINT TARGETS
      • IO ANTIBODY ENGINEERING
    • OGAP DISCOVERY PLATFORM
  • CAREERS
  • NEWS
    • PRESS RELEASES
  • CONTACT